Large cardiovascular outcomes trials have shown meaningful benefits for high-risk patients
The FDA approved Ozempic specifically for treating type 2 diabetes in adults
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may have a welcome benefit in addition to weight loss and glycemic control, with new data presented at ObesityWeek, the annual meeting of the Obesity Society, showing that use of these medications is associated with a reduction in problematic alcohol use
Developed as part of a new class of multi-receptor agonists, Retatrutide is designed to target several hormonal pathways involved in appetite regulation, glucose metabolism, and energy expenditure
Commonly studied for its role in tissue repair, angiogenesis, and cellular regeneration pathways
Hunterbrook published a follow-up on the potential benefits to Hims from the nominee for FDA commissioner, who was chief medical officer of a telehealth company that sells compounded GLP-1s